Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research, a journal of the American Association for Cancer Research. Read More…
The global, retrospective TARGET study evaluated the safety and efficacy of TheraSphere therapy in patients with hepatocellular carcinoma (HCC) – the most common type of primary liver cancer – using a dosing method known as multicompartment dosimetry, which maximizes the dose of Y-90 reaching the tumor while minimizing the radiation dose Read more…
International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes. Mesothelioma is caused by breathing asbestos particles and most commonly occurs in the linings of the lungs or abdomen. Currently, only seven per cent Read more…
In a study published in Nature Communications, researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma, progress to full-blown cancer. With further validation, Read more…
Colorectal cancer risk does not rise after bariatric surgery, a study from the University of Gothenburg shows. This finding is important for patients with obesity, and their healthcare professionals, when deciding upon such an operation. Read More…
The chronic complications, which occurred in 43% of patients, affected the joints and endocrine system most commonly, and less often involved salivary glands, eyes, peripheral nerves and other organs. These complications may be long lasting, with only 14% of cases having been resolved at last follow-up. This finding contrasted with Read more…
Patients with stage II pancreatic cancer who are treated with chemotherapy followed by resection (an operation that removes the cancerous part of the organ, structure or tissue) live nearly twice as long as patients who receive only chemotherapy, according to a new Journal of the American College of Surgeons study published online in advance of Read more…
At an 18-month analysis of the phase 2 OVARIO trial (NCT03326193), progression-free survival (PFS) benefit persisted in a majority of patients with advanced ovarian cancer who were previously treated with frontline platinum-based chemotherapy and bevacizumab (Avastin) and went on to receive combination therapy of niraparib (Zejula) and bevacizumab. These findings Read more…
Appointments for mammograms and other tests to detect potential cancers were canceled during lockdowns, possibly leading to undiagnosed malignancies. In some cases, the delay has come at a great cost. Read More…
After phase 2 trials showed promising survival for the combination of durvalumab during and after standard chemotherapy, collaborators in the US, Australia, and New Zealand open the phase 3 DREAM3R trial. Read More…